Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
CryoCath: Pulmonary vein isolation ablation with CryoCath's Arctic Front cryoballoon or Arctic Front plus the Freezor Max catheter resulted in maintenance of sinus rhythm in 74% of patients with paroxysmal atrial fibrillation (AF) and 42% of patients with persistent AF in a 346-patient trial led by Thomas Neumann, Kerckhoff Heart Center, Bad Nauheim, Germany. Treatment was considered successful if the patients were AF-free and off anti-arrhythmic drugs one year after a single procedure with the Arctic Front. The results appear in the July 22 Journal of the American College of Cardiology. CryoCath recently completed enrollment in the STOP AF pivotal U.S. trial for Arctic Front and expects FDA approval in late 2009. The device is already available in Europe (1"The Gray Sheet" March 31, 2008, In Brief)
You may also be interested in...
CryoCath down under
Montreal firm announces March 26 the introduction at two centers in Australia of its Arctic Front cryoablation balloon catheter for the treatment of paroxysmal, or episodic, atrial fibrillation. The device is already being used at 34 centers in Europe. CryoCath says it is on track to complete enrollment in its STOP AF pivotal U.S. trial in April, and anticipates a late 2009 PMA approval
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.